Amgen discontinues prostate cancer drug in $650M writedown, as obesity pipeline comes into focus in 2024
2023-10-31
临床1期并购
Amgen is taking a $650 million impairment charge from its acquisition of Teneobio, the biotech giant said Tuesday, as it shelves an experimental prostate cancer drug.
The writedown weighed on Amgen’s operating income for the third quarter, which fell from $2.7 billion a year ago to $2.0 billion this year. Amgen paid
$900 million upfront
in 2021 to buy the California biotech Teneobio and take over its lead cancer drug, which was renamed AMG 340. Amgen said it will discontinue an ongoing Phase I trial of AMG 340. In an interview ahead of earnings, Amgen CFO Peter Griffith said the decision was a “reprioritization” based on
positive Phase Ib results
from another prostate cancer drug candidate called xaluritamig, or AMG 509.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。